One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Kamada Ltd. logo
Kamada Ltd. KMDA
$ 7.76 0.04%
report update icon

Quarterly report 2025-Q4
added 05-06-2026

Kamada Ltd. Balance Sheet 2025-2011 | KMDA

Brief overview of Kamada Ltd.'s balance sheet strength

The balance sheet is assessed across five available annual reports spanning 2016 to 2020.

Assets advanced +111.3% to $210.7 million from $99.7 million; annual growth near 20.6% reflects a fast increase in scale.

Liability growth of -2.8% trailed asset growth of +111.3%. The funding structure became more resilient.

The equity ratio reached 84.8% from 66.9%. A high capital share reduces dependence on liabilities.

Negative net debt of -$70.2 million means cash holdings are larger than debt obligations.

The cash reserve occupies 33.3% of the balance sheet, previously 10%. It is one marker of short-term resilience.

The balance sheet includes a negative accumulated result of -$43.9 million. It should be assessed alongside historical profits and capital distributions.

Conclusion

Kamada Ltd.'s balance sheet looks resilient: assets are supported by substantial equity, while debt does not overwhelm financial flexibility.

Annual Balance Sheet Kamada Ltd.

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-63.9 M -67.4 M -46.8 M - - -70.2 M -38.4 M -17.4 M -11.3 M -8.19 M -4.86 M -7.1 M -42.9 M 7.25 M -1.94 M

Long Term Debt

9.44 M 9.43 M 7.44 M - - 36 K 4.24 M 716 K 1.37 M 1.36 M 151 K - 7.5 M 18.7 M 22.5 M

Long Term Debt Current

2.12 M 1.63 M 1.38 M 1.02 M - - - - - - - - - - -

Total Non Current Liabilities

62.2 M 63.4 M 61.3 M 70.7 M - 7.06 M 5.74 M 2.17 M 3.22 M 5.75 M 6.55 M 7.7 M 16.8 M 31.5 M 39.8 M

Total Liabilities

- - - - - 32 M 38.5 M 25.7 M 32.6 M 33 M 29.5 M 38.7 M 49.4 M 60.7 M 62.8 M

Deferred Revenue

- - - - - 222 K 589 K 461 K 4.93 M 4.9 M 1.92 M 2.92 M 5.45 M 8.18 M 7.27 M

Retained Earnings

-17.1 M -25.7 M -40.2 M -48.5 M - -43.9 M -52.2 M -73.7 M -95 M -102 M -95.6 M -83.5 M -72.8 M -80.7 M -88.9 M

Total Assets

379 M 372 M 355 M 322 M 319 M 211 M 174 M 138 M 122 M 99.7 M 102 M 119 M 139 M 89.1 M 85.4 M

Cash and Cash Equivalents

75.5 M 78.4 M 55.6 M 34.3 M 18.6 M 70.2 M 42.7 M 18.1 M 12.7 M 9.97 M 5.05 M - - - -

Book Value

379 M 372 M 355 M 322 M 319 M 179 M 135 M 112 M 89.5 M 66.7 M 72.5 M 80.4 M 90 M 28.4 M 22.7 M

Total Shareholders Equity

269 M 259 M 244 M 176 M - 179 M 135 M 112 M 89.5 M 66.7 M 72.5 M - - - -

All numbers in USD currency

Quarterly Balance Sheet Kamada Ltd.

2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

9.44 M 9.56 M 9.55 M 9.32 M 9.43 M 9.57 M 7.06 M 7.28 K 7.44 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

62.2 M 64.1 M 62.4 M 66.1 M 63.4 M 61.9 M 59 M 59.5 K 61.3 M 61.4 K 71.8 M 72.7 M - - - - 87.8 M 8.32 M - - 7.06 M 6.42 M - - 5.74 M - - - 2.17 M - - - 3.22 M - - - 5.75 M - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-17.1 M -20.6 M -25.9 M -33.3 M -25.7 M -29.5 M -33.4 M -37.8 K -40.2 M -45.3 K -48.5 M -50.3 M - - - - -46.2 M -41.2 M - - -43.9 M -45.6 M - - -61.1 M - - - -83 M - - - -105 M - - - -111 M - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

379 M 377 M 368 M 375 M 372 M 351 M 351 M 343 K 355 M 337 K 314 M 317 M - - - - 319 M 217 M - - 211 M 206 M - - 174 M - - - 138 M - - - 122 M - - - 99.7 M - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

75.5 M 72 M 66 M 76.2 M 78.4 M 72 M 56.5 M 48.2 K 55.6 M 52.6 K 21.8 M 27.1 M - - - - 18.6 M 99.8 M 68.4 M - 70.2 M 52.5 M 57.4 M - 42.7 M - - - 18.1 M - - - 12.7 M - - - 9.97 M - - - 5.05 M - - - 14.5 M - - - - - - - - - - - - - - -

Book Value

379 M 377 M 368 M 375 M 372 M 351 M 351 M 343 K 355 M 337 K 314 M 317 M - - - - 319 M 217 M - - 211 M 206 M - - 174 M - - - 138 M - - - 122 M - - - 99.7 M - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

269 M 265 M 260 M 252 M 259 M 255 M 251 M 247 K 244 M 238 K 177 M 175 M - - - - 177 M 182 M 182 M - 179 M 177 M 170 M - 135 M - - - 112 M - - - 89.5 M - - - 66.7 M - - - 72.5 M - - - 80.4 M - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Kamada Ltd., providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
Exicure Exicure
XCUR
$ 1.12 0.88 % $ 7.05 M usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
$ 1.04 1.36 % $ 104 M franceFrance
AbCellera Biologics AbCellera Biologics
ABCL
$ 11.8 2.51 % $ 3.52 B canadaCanada
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 55.9 0.22 % $ 7.48 B usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 54.68 1.65 % $ 10.5 B usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 27.53 3.93 % $ 1.83 B usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
$ 3.63 0.64 % $ 44.3 M israelIsrael
Jaguar Health Jaguar Health
JAGX
$ 3.53 9.81 % $ 8.23 M usaUSA
Protalix BioTherapeutics Protalix BioTherapeutics
PLX
$ 2.62 3.05 % $ 206 M israelIsrael
uniQure N.V. uniQure N.V.
QURE
$ 21.78 7.39 % $ 1.25 B niderlandNiderland
Stoke Therapeutics Stoke Therapeutics
STOK
$ 24.17 5.8 % $ 1.43 B usaUSA
Xencor Xencor
XNCR
$ 22.85 2.61 % $ 1.7 B usaUSA
Annexon Annexon
ANNX
$ 3.41 1.09 % $ 529 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 1.76 0.54 % $ 2.9 M israelIsrael
Incyte Corporation Incyte Corporation
INCY
$ 113.07 0.03 % $ 22.1 B usaUSA
Mesoblast Limited Mesoblast Limited
MESO
$ 13.28 1.16 % $ 16 B australiaAustralia
MeiraGTx Holdings plc MeiraGTx Holdings plc
MGTX
$ 9.28 5.1 % $ 746 M usaUSA
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
VRTX
$ 499.74 0.08 % $ 128 B usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 225.25 0.42 % $ 13.7 B danmarkDanmark
Axon Enterprise Axon Enterprise
AXON
$ 390.29 2.15 % $ 30.5 B usaUSA
AbbVie AbbVie
ABBV
$ 285.42 0.71 % $ 505 B usaUSA
Black Diamond Therapeutics Black Diamond Therapeutics
BDTX
$ 1.72 2.35 % $ 97.8 M usaUSA
Altimmune Altimmune
ALT
$ 2.2 2.16 % $ 194 M usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.22 2.39 % $ 809 M canadaCanada
Oncternal Therapeutics Oncternal Therapeutics
ONCT
- -24.12 % $ 1.56 M usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 11.84 0.87 % $ 1.06 B usaUSA
Seagen Seagen
SGEN
- - $ 42.2 B usaUSA
Codexis Codexis
CDXS
$ 1.24 5.43 % $ 108 M usaUSA
Cullinan Management Cullinan Management
CGEM
$ 12.93 2.64 % $ 779 M usaUSA
Compugen Ltd. Compugen Ltd.
CGEN
$ 1.96 4.0 % $ 183 M israelIsrael
Cellectar Biosciences Cellectar Biosciences
CLRB
$ 1.14 0.84 % $ 2.97 M usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
$ 11.32 0.17 % $ 4.7 B irlandaIrlanda
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Cocrystal Pharma Cocrystal Pharma
COCP
$ 1.02 0.49 % $ 11.5 M usaUSA
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 3.28 3.25 % $ 402 M usaUSA
Collegium Pharmaceutical Collegium Pharmaceutical
COLL
$ 23.19 0.04 % $ 734 M usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 4.52 4.39 % $ 60.2 M usaUSA
Curis Curis
CRIS
$ 0.41 1.4 % $ 5.4 M usaUSA
Corvus Pharmaceuticals Corvus Pharmaceuticals
CRVS
$ 9.52 5.01 % $ 752 M usaUSA
Vascular Biogenics Ltd. Vascular Biogenics Ltd.
VBLT
- -8.77 % $ 12.4 M israelIsrael
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
Histogen Histogen
HSTO
- 31.6 % $ 2.12 M usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
$ 24.02 0.39 % $ 3.64 B usaUSA
Denali Therapeutics Denali Therapeutics
DNLI
$ 17.61 2.63 % $ 3.04 B usaUSA
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 6.38 0.79 % $ 278 M usaUSA
ImmunoGen ImmunoGen
IMGN
- - $ 7.92 B usaUSA
Precision BioSciences Precision BioSciences
DTIL
$ 5.77 2.32 % $ 74 M usaUSA
Editas Medicine Editas Medicine
EDIT
$ 2.35 7.49 % $ 209 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 84.95 0.13 % $ 7.99 B usaUSA